2nd Jun 2006 14:39
2 June 2006Shire plc (the "Company")The Company announces that on 2 June 2006 The Honourable James A. Grant, P.C.,C.M., Q.C., a non-executive director of the Company, exercised an optiongranted to him under the BioChem Pharma Stock Option Plan and acquired 31,859ordinary shares of ‚£0.05p each in the Company at an option price of ‚£6.26 pershare. This option was due to expire on 4 June 2006.As a result of this transaction The Honourable James Grant has an interest,excluding unexercised share options, in 100,128 ordinary shares of ‚£0.05p eachin the Company. This represents 0.02% of the issued share capital of thatclass.T MayCompany SecretaryFor further information please contact:Investor Relations Clƒ©a Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system, gastrointestinal, generalproducts and human genetic therapies. The structure is sufficiently flexible toallow Shire to target new therapeutic areas to the extent opportunities arisethrough acquisitions. Shire believes that a carefully selected portfolio ofproducts with a strategically aligned and relatively small-scale sales forcewill deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. 2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire